Table 2.
Medications at Baseline and Follow‐Up
| Control Group (n=31) | EPA Group (n=31) | EPA+DHA Group (n=35) | P Value | |
|---|---|---|---|---|
| Baseline | ||||
| Strong statin | 4 (13) | 2 (6) | 9 (26) | 0.087 |
| Standard statin | 1 (3) | 1 (3) | 0 (0) | 0.562 |
| Aspirin | 4 (13) | 3 (10) | 4 (11) | 0.923 |
| Calcium channel blocker | 13 (42) | 7 (23) | 9 (26) | 0.199 |
| ACE inhibitor or ARB | 10 (32) | 8 (26) | 8 (23) | 0.683 |
| Beta blocker | 5 (16) | 2 (6) | 1 (3) | 0.134 |
| Insulin | 0 (0) | 0 (0) | 1 (3) | 0.409 |
| Oral hypoglycemic agent | 10 (32) | 1 (3)* | 7 (20) | 0.013 |
| Follow‐up | ||||
| Calcium channel blocker | 6 (19) | 8 (26) | 4 (11) | 0.322 |
| ACE inhibitor or ARB | 26 (84) | 28 (90) | 32 (91) | 0.589 |
| Beta blocker | 23 (74) | 25 (81) | 23 (66) | 0.389 |
| Insulin | 0 (0) | 0 (0) | 1 (2) | 0.409 |
| Oral hypoglycemic agent | 10 (32) | 2 (6)* | 7 (20) | 0.038 |
Values are n (percentage). ACE indicates angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; DHA, docosahexaenoic acid; and EPA, eicosapentaenoic acid.
*
P<0.05 vs control group.